On September 28th, Hangzhou Sumgen Biotechnology Co., Ltd. (hereinafter referred to as "Sumgen Biotech") announced that the first subject in the Phase I clinical trial of their independently developed innovative drug SG1827 had received the first dose. This marks another important milestone achieved following the successful initiation meeting held on September 19th for the SG1827 clinical study. The trial aims to evaluate the safety, tolerability, and preliminary efficacy of the drug in late-stage solid tumor patients. It is led by Professor Li Ning from the Cancer Hospital of the Chinese Academy of Medical Sciences and was first initiated at the Cancer Hospital of the Chinese Academy of Medical Sciences. Ms. Li Na, Vice President and Head of Clinical Development at Sumgen Biotech, stated, "The injectable SG1827 is a novel recombinant human CD80 mutant-Fc fusion protein independently developed by Sumgen Biotech, which has been rationally designed in terms of its mechanism of action, drug-like properties, and PK characteristics. Its pharmacological mechanism is clear, and preclinical study data suggest clear efficacy and good safety, positioning SG1827 as a leading drug in global drug development targeting the same pathway. Building upon the tremendous success of tumor immunotherapy represented by anti-PD-1/PD-L1 antibodies, the future important research direction is to synergistically activate the body's immune system through multiple strategies to enhance anti-tumor activity while ensuring safety. The focus of SG1827 clinical development is to explore the potential of synergistic therapy with anti-PD-1/PD-L1 antibodies in the treatment of malignant tumors. The rapid initiation and progress of this clinical study are particularly attributable to the strong support of Professor Li Ning, the leadership at the hospital, and the research team at the Cancer Hospital of the Chinese Academy of Medical Sciences, as well as the collective efforts of the project team. We look forward to the swift progress and positive developments of this project, benefiting more late-stage cancer patients!"
About SG1827 SG1827 is an immune modulator independently developed by Sumgen Biotech. One of its primary mechanisms of action is to provide co-stimulatory signals for T cell activation, which plays a crucial role in promoting immune cell recognition and attack of tumors, thus contributing to enhancing the clinical efficacy of anti-PD-1/PD-L1 antibodies and other immunotherapies. Preliminary studies have shown that SG1827, either as a monotherapy or in combination with other immune checkpoint antibodies, demonstrates significant anti-tumor activity with good safety and no significant cytokine release. The Phase I clinical trial of SG1827 is an Ia/Ib clinical study aimed at evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of SG1827 in late-stage solid tumor patients.
Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044
